Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 3Phase EARLY_PHASE1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostate Cancer Recurrent 1Osteosarcoma 1Melanoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Hydroxychloroquine × 90 days × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

NCT05036226 2026-05-13

COAST

Medical University of South Carolina

Phase 1/2 Recruiting
76 enrolled
GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting
94 enrolled
Dermatologic

Melanoma

NCT05842174 2026-04-16

TAQE

VA Office of Research and Development

Phase 1/2 Recruiting
93 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡